Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

Recombinant plasmid DNA and attenuated poxviruses are under development as cancer and infectious disease vaccines. We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epi...

全面介紹

書目詳細資料
Main Authors: Smith, C, Dunbar, P, Mirza, F, Palmowski, M, Shepherd, D, Gilbert, S, Coulie, P, Schneider, J, Hoffman, E, Hawkins, R, Harris, A, Cerundolo, V
格式: Journal article
語言:English
出版: 2005